Posted by Michael Wonder on 30 Jun 2026
Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours
29 June 2026 - Based on three Phase II trials of AstraZeneca and Daiichi Sankyo’s Enhertu which demonstrated clinically meaningful responses across a broad range of tumours.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumours who have received prior treatment and who have no satisfactory treatment options.
